In its response to the statement of objections, Aventis argues that the depressed state of the methylglucamine market should be seen as an attenuating circumstance(150).
Recital 252, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002
In its response to the statement of objections, Aventis argues that the depressed state of the methylglucamine market should be seen as an attenuating circumstance(150).